一项试验显示,在没有心脏病的高风险成年人中,evolcumab可降低心脏病风险. A trial shows evolocumab cuts heart risks in high-risk adults without prior heart issues.

一项大型临床试验VESALIUS- CV发现,在没有心脏病发作或中风的高危成年人中,将evolocumab添加到强化降胆固醇治疗中,显著降低了首次重大心血管事件的风险. A large clinical trial, VESALIUS-CV, found that adding evolocumab to intensive cholesterol-lowering therapy significantly reduced the risk of first major cardiovascular events in high-risk adults without prior heart attacks or strokes. 在4. 6年的中位随访期内,接受evolocumab治疗的患者患心脏病,心脏病发作或缺血性中风的死亡风险降低了25%,心脏病发作风险降低了36%,心血管死亡风险降低了27%. Over a median follow-up of 4.6 years, patients on evolocumab had a 25% lower risk of death from heart disease, heart attack, or ischemic stroke, a 36% lower heart attack risk, and a 27% lower risk of cardiovascular death, heart attack, or stroke. 该药物将LDL胆固醇降低到45毫克/dL的中位数。 The drug lowered LDL cholesterol to a median of 45 mg/dL. 研究结果在《新英格兰医学杂志》上发表,并在2025年美国心脏协会科学会议上发表,支持在患无环球硬化症或高风险糖尿病的高风险患者中,使用evolocumab进行初级预防,这是第一证据,表明PCSK9抑制因素改善了这一群体的成果。 Results, published in the New England Journal of Medicine and presented at the 2025 American Heart Association Scientific Sessions, support using evolocumab for primary prevention in high-risk patients with atherosclerosis or high-risk diabetes, marking the first evidence of a PCSK9 inhibitor improving outcomes in this group.